Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The company also has developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES.
The company reported today that it has signed an exclusive license agreement with the University of Maryland, Baltimore, for its NPDCS platform. It is a result of initial funding through a Maryland Industrial Partnership (MIPS) award. The awards are intended to foster relationships between Maryland universities and industries.
This particular technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. Rexahn’s NPDCS platform combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a signaling component.
This approach reduces the levels of anti-cancer agents circulating in the body, which substantially lowers the risk possible adverse side effects while maximizing anti-tumor activity. Rexahn’s delivery method has been shown to result in increased efficacy and reduced toxicity and beats other current delivery methods.
For additional information about Rexahn Pharmaceuticals, please visit www.rexahn.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
